All News

Explore essential insights on cervical cancer screening, patient engagement, and innovative self-collection methods this Gynecologic Cancer Awareness Month.

If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.

Incyte announced the agency's decision, which was based on findings of significant reduction in atopic dermatitis signs and symptoms during the TRuE-AD3 clinical trial.

Discussions on day 1 focused on the difference between the MMR and MMR+V vaccines, with clinicians calling for inclusion of real-world experience in any ACIP decision.

EADV 2025: Guttman-Yassky presented data from the phase 3 ROCKET-IGNITE trial and highlights its importance in the context of the global ROCKET development program.

Your daily dose of the clinical news you may have missed.

EADV 2025: Phase 3 ROCKET-SHUTTLE results showed the T-cell rebalancing therapy significantly improved AD signs and symptoms in treatment-experienced adults.

Ada Stewart, MD, reviews current guidelines, addresses patient hesitancy, and explains how HPV self-collection tests may expand screening options in primary care.

The novel IL-22 blocker was associated with improvements in EASI as early as week 1 for lower doses and week 2 for the highest dose, compared with placebo.

The updated prescribing information includes phase 3b BATURA trial results showing a 46% reduction in severe exacerbations in mild asthma vs albuterol.

In children aged 10 to <18 with T2D inadequately controlled on standard of care treatment, tirzepatide reduced HbA1c by an average of 2.2% and reduced BMI as well.

Atypical causes of MI in women included spontaneous coronary artery dissection, which was 6 times more common in women than in men, a Mayo Clinic study found.

Regardless of decisions made during the ACIP meeting, health insurance plans will continue to cover shots recommended by ACIP as of Sept 1.

Among 180+ active AD trials, 15 biological targets span traditional Aβ and tau proteins as well as new pathways in brain metabolism, neuroinflammation, and synaptic health.

This week’s podcast episode covers cervical cancer disparities, HPV awareness, depression risk, pharmacy CRC screening, and semaglutide approval for MASH.

EADV 2025: Data will highlight the PDE4 inhibitor's efficacy across diverse populations and 3 common skin conditions: seborrheic dermatitis, atopic dermatitis, and psoriasis.

EASD 2025. A new oral GLP-1 receptor agonist, orforglipron, shows promise for significant weight loss and improved cardiometabolic health in adults with obesity.

EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.